{
    "nctId": "NCT00313170",
    "briefTitle": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg",
    "officialTitle": "Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 144,
    "primaryOutcomeMeasure": "Objective Response (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor.\n* Requiring hormonal treatment.\n* Postmenopausal women (woman who has stopped having menstrual periods)\n\nExclusion Criteria:\n\n* Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced BC.\n* Treatment with more than one previous regimen of endocrine therapy for advanced BC.\n* An existing condition that prevents compliance.",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}